At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 213 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Golimumab 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis
In Brief
A Phase 3 clinical trial evaluating Placebo, Golimumab, and 1 other intervention for Ankylosing Spondylitis. Completed, enrolled 213 participants across 7 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with ankylosing spondylitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedNov 2010
Primary CompletionMay 2011
Study CompletionMar 2012
TodayJul 2026
First PostedNov 25, 2010
Enrollment StartOct 1, 2010
Primary CompletionMay 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.6 years ago
Interventions
Placebodrug
Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
Golimumabdrug
Golimumab 50 mg SC injection every 4 weeks for 48 weeks
Golimumab (placebo group)drug
Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48